Abbott’s system continuously monitors glucose data but it can’t display that data on a continuous basis. Instead, users can check the data whenever they want using a neaf-field communication scanner.

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

Dexcom has won a nod from FDA for the G7 15-Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. With this clearance, the San Diego, CA-based company continues to ...

On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 diabetes using insulin therapy, as well as certain non-insulin users who ...

Dexcom is continuing to build upon its continuous glucose monitoring (CGM) story with a new nod from FDA. The San Diego-based company received clearance from the federal agency for the Dexcom G6 Pro ...

It’s buff versus buffet in the latest DTC ad battle of continuous glucose monitors. While Dexcom continues its blood-sugar monitoring campaign with musician and heartthrob Nick Jonas, Abbott takes a ...

It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...

DexCom, Inc. DXCM is well-positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 ...